CTI Announces That The EORTC Completes Enrollment In Phase II …
Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma had sufficient activity based …
More: continued here